Physician profile
Levy Wallace
NPI 1831719038
$924.22
in general payments reported to CMS, 2019-2025
12 companies · $590 in 2025
The $590 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $24.42 · 2023: $25.90 · 2024: $284 · 2025: $590.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $900.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $899.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $316.70 | 2024-2025 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $156.08 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $122.20 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $78.21 | 2024-2025 | Jardiance, Synjardy, Tradjenta |
| Pfizer INC. | $63.78 | 2022-2024 | |
| Lilly USA, LLC | $48.34 | 2025 | Mounjaro, Zepbound |
| Lundbeck LLC | $29.49 | 2024 | Vyepti |
| Agios Pharmaceuticals, INC. | $23.77 | 2025 | Pyrukynd |
| Amgen INC. | $23.24 | 2025 | Evenity |
| Phathom Pharmaceuticals, INC. | $23.12 | 2024 | Voquezna |
| Madrigal Pharmaceuticals | $20.48 | 2025 | Rezdiffra |
| E.R. Squibb & Sons, L.L.C. | $18.81 | 2025 | Eliquis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Levy Wallace listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.